Sanofi has signed a research pact with Audion Therapeutics to develop treatments targeting hearing loss by optimizing small molecules while using regenerative medicine approach.
Subscribe to our email newsletter
As per the two-year agreement, the companies will use technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory by investigator and Audion co-founder Albert Edge.
Further, Audion could license technology rights to Sanofi in connection with the research conducted under the current deal.
Sanofi Global Research & Development president Elias Zerhouni said this collaboration is a multi-disciplinary approach with their internal Aging Therapeutic Strategic Unit and Early-to-Candidate Unit working together to advance novel therapies in the field of otolaryngology using advanced technologies available to study cochlear biology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.